Citizen Health Partner to Support Drug Development and Long-Term Patient Outcomes in PKP2 Cardiomyopathy

Collaboration aims to enhance clinical study experience and accelerate therapeutic innovation for arrhythmogenic cardiomyopathy caused by PKP2 mutations

SAN FRANCISCO and NEW YORK, May 7, 2025 /PRNewswire/ — Citizen Health today announced a strategic partnership to support Rocket Pharmaceutical Inc.’s (Rocket Pharma) clinical and long-term data initiatives for arrhythmogenic cardiomyopathy (ACM) caused by mutations in the PKP2 gene.

PKP2-ACM is a rare inherited heart disorder characterized by fibrofatty replacement of the heart muscle, arrhythmias, risk of sudden cardiac death, and progressive heart failure. There are currently no approved therapies that target the underlying genetic cause, creating a critical need for innovative approaches that address both the clinical and patient experience challenges in this complex condition.

To help overcome these barriers, Citizen Health is collaborating with Rocket Pharma to build a comprehensive, patient-consented natural history registry. By aggregating over 10 years of longitudinal clinical data directly from patient medical records, Citizen Health will generate real-world insights to inform trial design, regulatory strategy, and long-term patient management.

“We’re proud to partner with Rocket Pharmaceuticals on a program that truly reimagines what patient-centered research can look like. By combining deep clinical insights with a seamless patient experience, we’re helping reduce the burden of participation while generating the kind of longitudinal data that drives smarter, faster drug development. Together, we’re setting a new standard for how clinical trials can support patients not just during the study, but well beyond it,” said Farid Vij, CEO, Citizen Health.

Unlike traditional registries, this partnership extends beyond data collection. Citizen Health and Rocket Pharma will collaborate to enroll patients already participating in Rocket Pharma’s PKP2-ACM Natural History Study (https://clinicaltrials.gov/study/NCT06644742), providing patients with the full suite of Citizen Health’s services—including access to their complete medical records and health insights.

“At Rocket, our commitment to patients goes far beyond the clinic. By partnering with Citizen Health, we are not only building a deeper understanding of PKP2 cardiomyopathy through rich, real-world data, but also supporting patients throughout their journey,” said Dr. Mayur Kasetty, AAV Global Program Head, Rocket Pharmaceuticals. “This collaboration reflects our belief that patient-centered innovation is essential to accelerating meaningful therapies.”

About Citizen Health
Citizen Health is a consumer health platform that transforms how patients and life sciences companies collect, use, and benefit from real-world health data. By empowering individuals with access to their full medical history and providing AI-driven health advocacy, Citizen improves patient care while accelerating the development of therapies.

Forward-Looking Statements
This press release contains forward-looking statements regarding the potential outcomes of the partnership between Rocket Pharmaceuticals and Citizen Health. Actual results may differ materially due to risks and uncertainties inherent in clinical development and regulatory review processes.

Contacts
Nasha Fitter
Co-Founder and Chief Business Officer, Citizen Health
(206) 604-0240
nasha.fitter@citizen.health

View original content to download multimedia:https://www.prnewswire.com/news-releases/citizen-health-partner-to-support-drug-development-and-long-term-patient-outcomes-in-pkp2-cardiomyopathy-302447900.html

SOURCE Citizen Health